WallStSmart

Crowdstrike Holdings Inc (CRWD)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Crowdstrike Holdings Inc generates 149% more annual revenue ($4.81B vs $1.93B). VISN leads profitability with a 118.2% profit margin vs -3.4%. VISN appears more attractively valued with a PEG of 2.94. VISN earns a higher WallStSmart Score of 58/100 (C).

CRWD

Hold

40

out of 100

Grade: D

Growth: 9.3Profit: 2.5Value: 3.7Quality: 5.5
Piotroski: 2/9Altman Z: 0.98

VISN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 4.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CRWDOvervalued (-11.3%)

Margin of Safety

-11.3%

Fair Value

$400.68

Current Price

$445.75

$45.07 premium

UndervaluedFair: $400.68Overvalued
VISNSignificantly Overvalued (-47.1%)

Margin of Safety

-47.1%

Fair Value

$13.03

Current Price

$12.79

$0.23 premium

UndervaluedFair: $13.03Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRWD4 strengths · Avg: 9.0/10
EPS GrowthGrowth
533.0%10/10

Earnings expanding 533.0% YoY

Market CapQuality
$114.73B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

VISN4 strengths · Avg: 9.0/10
Profit MarginProfitability
118.2%10/10

Keeps 118 of every $100 in revenue as profit

Revenue GrowthGrowth
50.6%10/10

Revenue surging 50.6% year-over-year

P/E RatioValuation
17.6x8/10

Attractively priced relative to earnings

Operating MarginProfitability
29.1%8/10

Strong operational efficiency at 29.1%

Areas to Watch

CRWD4 concerns · Avg: 2.5/10
Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.732/10

Expensive relative to growth rate

Price/BookValuation
25.5x2/10

Trading at 25.5x book value

VISN3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

PEG RatioValuation
2.942/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CRWD

The strongest argument for CRWD centers on EPS Growth, Market Cap, Debt/Equity. Revenue growth of 23.3% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Profit Margin, Revenue Growth, P/E Ratio. Profitability is solid with margins at 118.2% and operating margin at 29.1%. Revenue growth of 50.6% demonstrates continued momentum.

Bear Case : CRWD

The primary concerns for CRWD are Operating Margin, Piotroski F-Score, PEG Ratio.

Bear Case : VISN

The primary concerns for VISN are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

VISN carries more volatility with a beta of 2.38 — expect wider price swings.

VISN is growing revenue faster at 50.6% — sustainability is the question.

CRWD generates stronger free cash flow (376M), providing more financial flexibility.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VISN scores higher overall (58/100 vs 40/100), backed by strong 118.2% margins and 50.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crowdstrike Holdings Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

CrowdStrike Holdings, Inc. provides cloud solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. The company is headquartered in Sunnyvale, California.

Visit Website →

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?